Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)

Contract Value

Not provided

Codes & Classification
Solicitation Number

ARPA-H-SOL-25-122

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

NONE

Place of Performance

Washington, District of Columbia, UNITED STATES

SourceSAM
The Advanced Research Projects Agency for Health (ARPA-H), operating under the Department of Health and Human Services and the National Institutes of Health, has issued a solicitation for the Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) program (Procurement Identifier: ARPA-H-SOL-25-122). This initiative seeks to catalyze the development of transformative, one-time therapeutic interventions for hereditary rare diseases, leveraging cutting-edge precision genetic medicine technologies. The ultimate vision is to enable patients to access treatments that can slow, reverse, or potentially cure their conditions by directly addressing the genetic causes of disease. The scope of the THRIVE program encompasses research and development activities in biotechnology, specifically excluding nanobiotechnology, as classified under NAICS code 541714. The program is designed to support innovative solutions that harness advances in genetic understanding and therapeutic delivery, with the goal of revolutionizing the treatment landscape for rare hereditary diseases. Key requirements and objectives for this procurement include the submission of comprehensive solution summaries by October 31, 2025, at 11:59 PM ET. Proposers are expected to articulate their technical and management approaches, cost proposals, and administrative and policy compliance, following the detailed instructions provided in the Innovative Solutions Opening (ISO) and its subsequent amendments. Notably, the ISO has undergone several amendments to clarify proposal requirements, reporting schedules, and submission processes. For example, cost sharing is now strongly encouraged rather than mandatory, and multi-party teaming arrangements are no longer required. The reporting requirement has shifted from quarterly to bi-annual, and certain proposal volumes and sections are only required if a proposer is invited to negotiate an award. The evaluation process includes a virtual PowerPoint presentation, with slides, a Gantt chart, and an optional appendix to be submitted by December 22, 2025, at 3:00 PM ET. Presentations are scheduled to occur between January 5 and January 16, 2026. Templates for the Statement of Work and Milestone Payment Schedule are provided and should be used as applicable. The cost proposal spreadsheet is due with the full proposal submission by February 5, 2026, at 3:00 PM ET. The place of performance for this opportunity is Washington, District of Columbia (DC), United States. There are no set-aside requirements for this solicitation, making it open to all qualified entities. The Product Service Code associated with this procurement is AN13. Contractors interested in this opportunity should note that ARPA-H is seeking proposals that demonstrate a clear path to regulatory innovation, sustainable deployment models, and robust data management and sharing plans. The agency has also clarified its role in regulatory facilitation and encourages cost-sharing arrangements to maximize program impact. The primary point of contact for this solicitation is the THRIVE Program, reachable at [email protected]. Additional information, including the full ISO, amendments, templates, and FAQs, can be accessed via the official SAM.gov opportunity listing (Opportunity ID: e2dfbdba502742c480b847d537e78e72) at https://sam.gov/opp/e2dfbdba502742c480b847d537e78e72/view. Interested parties are encouraged to review all attachments and amendments carefully to ensure compliance with the latest requirements. This solicitation represents a significant opportunity for organizations with expertise in biotechnology research and development, particularly those focused on genetic medicine and rare disease therapeutics, to contribute to a high-impact federal initiative aimed at transforming patient outcomes through innovative science and technology.
Documents13